Physician profile
John M Holsinger
NPI 1992997548
$6,268.31
in general payments reported to CMS, 2019-2025
34 companies · $1,811 in 2025
The $1,811 reported for 2025 was more than what a typical Dermatology provider received nationally (typical 2025 total: $772).
Payments by year
General payments by program year, as reported to CMS.
General payments by year: 2019: $1,655 · 2020: $375 · 2022: $385 · 2023: $724 · 2024: $1,319 · 2025: $1,811.
What the payments were for
Nature of payment as categorized by the reporting companies: meals, consulting, travel, and so on.
Food and Beverage: $3,707 · Education: $147.
View as a table
| Payment type | Amount (2023-2025) |
|---|---|
| Food and Beverage | $3,706.99 |
| Education | $146.69 |
Payment-type detail covers 2023-2025; earlier years are included in totals but not broken out here.
Who reported paying
General payments only, as reported to CMS. Product names cover 2023-2025.
| Company | General payments | Years | Top products |
|---|---|---|---|
| Abbvie INC. | $1,371.31 | 2019-2025 | |
| Regeneron Healthcare Solutions, INC. | $630.34 | 2019-2025 | Dupixent, Libtayo |
| Janssen Biotech, INC. | $618.10 | 2019-2025 | Tremfya, Simponi, Simponi Aria |
| Dermavant Sciences, INC. | $536.60 | 2023-2024 | Vtama |
| Sun Pharmaceutical Industries INC. | $367.25 | 2019-2024 | Winlevi, Absorica Ld |
| E.R. Squibb & Sons, L.L.C. | $313.09 | 2022-2025 | Sotyktu |
| Genzyme Corporation | $293.40 | 2024-2025 | |
| Organon LLC | $286.65 | 2024-2025 | Vtama |
| Ucb, INC. | $280.81 | 2019-2025 | Bimzelx, Cimzia |
| Novartis Pharmaceuticals Corporation | $269.86 | 2019-2025 | |
| Pfizer INC. | $232.84 | 2019-2025 | |
| Galderma Laboratories, L.P. | $148.96 | 2019-2025 | |
| Lilly USA, LLC | $130.38 | 2019-2025 | Ebglyss, Taltz |
| Janssen Scientific Affairs, LLC | $112.88 | 2019 | |
| Prugen, INC. Pharmaceuticals | $85.00 | 2019 |
Show all 34 companies
| Company | General payments | Years | Top products |
|---|---|---|---|
| Ortho Dermatologics, A Division of Bausch Health US, LLC | $83.75 | 2019-2024 | Cabtreo |
| Celgene Corporation | $76.99 | 2019 | |
| Leo Pharma INC. | $63.28 | 2019 | |
| Mayne Pharma Commercial LLC | $59.75 | 2019-2025 | |
| Aclaris Therapeutics, INC. | $40.34 | 2019 | |
| Taro Pharmaceuticals USA, INC. | $30.37 | 2019 | |
| Vyne Pharmaceuticals INC. | $28.72 | 2020 | |
| Mission Pharmacal Company | $28.31 | 2019-2020 | |
| Incyte Corporation | $26.61 | 2025 | Opzelura |
| Arcutis Biotherapeutics, INC. | $22.78 | 2024 | Zoryve |
| Boehringer Ingelheim Pharmaceuticals, INC. | $22.29 | 2025 | Spevigo |
| Amgen INC. | $17.94 | 2024 | Otezla |
| Genentech USA, INC. | $14.61 | 2019 | |
| Mylan Pharmaceuticals INC. | $13.34 | 2019 | |
| Janssen Pharmaceuticals, INC | $13.17 | 2025 | Tremfya |
| Almirall LLC | $12.90 | 2023 | Klisyri |
| Promius Pharma LLC | $12.71 | 2019 | |
| Merck Sharp & Dohme LLC | $11.77 | 2019 | |
| Dermira, INC. | $11.21 | 2019 |
Drugs and devices associated with these payments
CMS records which products a payment was associated with, not how the money was allocated. Association is not allocation: one payment can be associated with several products, and a product listing does not mean the payment was made because of that product. Product detail covers 2023-2025.
If you want to bring it up
Most clinicians are glad to talk about this. A respectful way in:
- "I saw John Holsinger listed in the CMS Open Payments database. Can you tell me about your work with those companies?"
- "Is there a generic or alternative to this medication, and would it work as well for me?"
- "What made you choose this particular treatment for my situation?"
These are normal questions. A good clinician will welcome them.
Share this page
Keep an eye on this page
Get an email when the next June refresh changes this page. No account needed.
Source: CMS Open Payments, program years 2019-2025, as reported to CMS by drug and device makers (published June 30, 2026). Drug and device detail covers 2023-2025.